Adaptam Therapeutics

Adaptam Therapeutics is pioneering next-generation cancer immunotherapies by disrupting the immunosuppressive myeloid tumor microenvironment (TME) through glyco-immune checkpoints. The TME in solid tumors is enriched in immunosuppressive myeloid cells, such as tumor-associated macrophages (TAMs), which drive resistance or a lack of response to existing treatments. This remains one of the toughest challenges in cancer immunotherapy. Our discoveries in cancer immunology, T cell and myeloid cell biology have revealed previously unexplored cancer dependencies, demonstrating that specific glycan interactions with immune cells are key drivers of myeloid-mediated immune suppression. Adaptam is advancing a pipeline of first-in-class, antibody-based therapies targeting these central glycobiology pathways involved in myeloid immunosuppression. Our in-house antibody discovery expertise enables the development of antibody-drug conjugates (ADCs) and bispecific antibodies targeting the immunosuppressive TME. Focused on solid tumors, our programs are designed to transform cancer treatment across multiple indications by reprogramming the immunosuppressive tumor landscape while boosting T cell activity. A spin-off from CIC bioGUNE, Adaptam is supported by founding investor Criteria Bio Ventures and has secured competitive national and European funding, including several prestigious European Research Council (ERC) grants.